Education
About Us
Working with TipRanks
Follow Us
Stengone Carmine N. Insider Profile
4 Followers
Stengone Carmine N., Director at Kiora Pharmaceuticals, holds 14.95K shares in Contineum Therapeutics, Inc. Class A (Ticker: CTNM), holds 1.25K shares in Kiora Pharmaceuticals (Ticker: KPRX).
Stengone Carmine N. has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Stengone Carmine N. holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Stengone Carmine N.
Stengone Carmine N.'s Trading History
Kiora Pharmaceuticals
Sep 12, 2024
Director
Informative Buy
4.60K
$2.54K
Contineum Therapeutics, Inc. Class A
Feb 26, 2026
CEO & President, Director
Uninformative Buy
8.95K
$181.09K
List of latest transactions for each holding click on a transaction to see Stengone Carmine N.'s performance on stock
You May Also Like
Stengone Carmine N. insider profile FAQ
What is the percentage of profitable transactions made by Stengone Carmine N.?
The percentage of profitable transactions made by Stengone Carmine N. is ―.
What is the average return per transaction made by Stengone Carmine N.?
The average return per transaction made by Stengone Carmine N. is ―.
What stocks does Stengone Carmine N. hold?
Stengone Carmine N. holds: KPRX, CTNM stocks.
What was Stengone Carmine N.’s latest transaction?
Stengone Carmine N. latest transaction was an Uninformative Buy of $8.95K.
What was Stengone Carmine N.'s most profitable transaction?
Stengone Carmine N.’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Stengone Carmine N.'s role in Kiora Pharmaceuticals?
Stengone Carmine N.'s role in Kiora Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.